Please, wait while we are validating your browserThe many uses of medical marijuana have been known for years in the healthcare community.However, many healthcare professionals felt uncomfortable about prescribing the drug as a form of treatment, because of the stigma and prejudice still associated with the plant.But an Israeli tech startup decided to take matters into their own hands and provide doctors with a way to professionally and safely administer medical marijuana to their patients.Syqe Medical, a company based out of Tel-Aviv, created the world's first 3D printed marijuana inhaler which can be used to provide precise doses of marijuana at distance.This will allow doctors to remotely administer the drug to users without the risk for abuse.The inhaler has already received the stamp of approval from Israel's health ministry and has already been used in the Rambam hospital located in Haifa for over a year.Another thing that sets this inhaler apart is the fact that it is manufactured using 3D printing technology, something that was unheard of to this point in the world of marijuana inhalers.

The device comes in two versions, one geared toward healthcare facilities and one for individuals.spyre vaporizerThe hospital version of the inhaler comes with an interface designed for use by healthcare professionals and allows caregivers to administer doses remotely.vaporizer safety studyThe unit was specifically created for use in cancer centers, pain clinics, intensive care and other healthcare institutions.The personal version is much smaller than the one designed for healthcare facilities, and comes loaded with cannabis cartridges, each containing 100 micrograms of the drug.match free vaporizer sly penThe unit features an air flow and thermal controller, wireless connectivity to a database that will be used by physicians and other healthcare professionals, and lung interfacing among other things.Syqe recently struck a distribution and marketing deal with Teva pharmaceuticals to make the inhaler available across Israel and the country's health ministry has already approved the device for use nationwide.e cigarette x fire

The device offers obvious advantages to users of medical marijuana.e cigarette neo classicFirst of all, inhalers use vaporization instead of combustion, a process that allows the plant to be heated just enough for the cannabis molecules to evaporate and be inhalable.e cigarette victoriaPreventing combustion greatly reduces the amount of carcinogens inhaled in the process.Another great advantage of the device is that it will provide doctors and physicians with a way to track a user’s consumption and adjust doses accordingly.volcano vaporizer tacomaSince the devices will be connected to a database, the system will allow professionals to gather important data on optimal dosage for a variety of illnesses.Zivio represents a major breakthrough in the world of medical marijuana.tartarini vaporizer

It allows medical professionals to track exactly how much marijuana should be prescribed and also allows them to oversee consumption even if they aren't present.We can expect many other companies to follow in Syqe’s footsteps and release similar products in the coming years, providing patients with a whole new spectrum of possibilities.lsmoke thunder vaporizer reviewChronic neuropathic pain is often refractory to standard pharmacological treatments.Although growing evidence supports the use of inhaled cannabis for neuropathic pain, the lack of standard inhaled dosing plays a major obstacle in cannabis becoming a “main stream” pharmacological treatment for neuropathic pain.The objective of this study was to explore the pharmacokinetics, safety, tolerability, efficacy, and ease of use of a novel portable thermal-metered-dose inhaler (tMDI) for cannabis in a cohort of eight patients suffering from chronic neuropathic pain and on a stable analgesic regimen including medicinal cannabis.

In a single-dose, open-label study, patients inhaled a single 15.1 ± 0.1 mg dose of cannabis using the Syqe Inhaler device.Blood samples for Δ9-tetrahydrocannabinol (THC) and 11-hydroxy-Δ9-THC were taken at baseline and up to 120 minutes.Pain intensity (0–10 VAS), adverse events, and satisfaction score were monitored following the inhalation.A uniform pharmacokinetic profile was exhibited across all participants (Δ9-THC plasma Cmax ± SD was 38 ± 10 ng/mL, Tmax ± SD was 3 ± 1 minutes, AUC0→infinity ± SD was 607 ± 200 ng·min/mL).Higher plasma Cmax increase per mg Δ9-THC administered (12.3 ng/mL/mg THC) and lower interindividual variability of Cmax (25.3%), compared with reported alternative modes of THC delivery, were measured.A significant 45% reduction in pain intensity was noted 20 minutes post inhalation (P = .001), turning back to baseline within 90 minutes.Tolerable, lightheadedness, lasting 15–30 minutes and requiring no intervention, was the only reported adverse event.

This trial suggests the potential use of the Syqe Inhaler device as a smokeless delivery system of medicinal cannabis, producing a Δ9-THC pharmacokinetic profile with low interindividual variation of Cmax, achieving pharmaceutical standards for inhaled drugs.KEYWORDS : analgesiainhalationmedicinal cannabispainneuropathic painpharmacokineticsΔ9-THCvaporization Article Metrics 0 0 7Eaze fulfills a simple function: Push button, get pot.The average order is around $10 and cannabis can be delivered in as little as 15 minutes, said Eaze CEO Keith McCarty.But unlike its customers — marijuana dispensaries — Eaze is a tech company and one of a growing number of cannabis tech start-ups using data to offer products and services to the pot industry.According to polls, recreational marijuana legalization measures are likely to pass, albeit narrowly, in all five states where they are on the ballot Tuesday: Arizona, California, Maine, Massachusetts and Nevada.Four other states — Montana, North Dakota, Arkansas and Florida — have ballots proposing at least some form of medical marijuana legalization.

Tuesday's vote is set to open up giant new market opportunities over the next several years.Nationally, legal sales of marijuana will reach $7.4 billion this year and surpass $20.6 billion by 2020, with recreational marijuana sales making up about 53 percent of the market, according to Arcview Market Research."A lot of the fastest growing cannabis companies are data driven, said McCarty, who helped start workplace social network Yammer, bought by Microsoft in 2012 for $1.2 billion."There are not very many of them, but as the industry continues to evolve, the data-driven companies will be most successful."Eaze technology powers on-demand deliveries to 200,000 medical marijuana patients in 100 California cities.Its Uber-like app connects patients with dispensaries and powers deliveries.The company provides data to help retailers predict supply and demand so they know how many delivery drivers they will need at any given time and what products those drivers should carry, said McCarty.Eaze does not employ the drivers directly — that is left to the dispensaries — but does conduct driver background checks before passing along applicants.

A separate app can connect California residents with a doctor for an evaluation.The start-up launched in California in 2014 to serve medical marijuana patients and can easily adapt its software for so-called adult or recreational use, said McCarty.Because it is a tech platform, it is an easy business to scale up with demand, he said.The company has raised $25 million in venture funding and is among the most well-funded cannabis tech companies.Eaze has amassed a vast trove of sales data and is putting it to use for its dispensary customers.For example, the most popular product is still dried marijuana plants, though marijuana oil cartridges for vaporizers have taken off this year — growing three fold as a proportion of sales — and are almost as popular as traditional weed in the San Francisco Bay Area, Eaze has found.Northern Californians prefer the sativa strain (57 percent) and generally buy cannabis at night.Southern Californians prefer the indica strain (61 percent) and spread their buying throughout the day.

Insights like these will help Eaze scale its business as the marijuana industry grows.Women make up a growing share of medical marijuana consumers, and accounted for 27 percent of sales in October, up from 25 percent in January.Over that same time period, sales of medical marijuana to patients ages 25 to 55 have increased, sales to younger users 18 to 25 have declined, and sales to seniors have held steady, Eaze has found.Data-driven cannabis start-ups are attracting a ton of funding in areas such as subscription e-commerce, compliance, tracking, payments, banking, data analytics, order management and social networking, CB Insights found."Cannabis technology will soar, but the federal government will decline to solve the problems around banking, transportation and interstate commerce," said Bradley Tusk, who leads Tusk Ventures, which specializes in advising and investing in start-ups facing tough regulatory environments.Tusk has invested in Eaze.Eaze is far from alone.The Denver-based MJ Freeway has developed patented seed-to-sale agricultural tracking products that enable marijuana license holders to manage their businesses and comply with regulation.

Its clients include cultivators, manufacturers, retailers and state and local government agencies.The company will unveil a new product at the Marijuana Business Conference & Expo next week.Since launching in 2010, MJ Freeway has amassed 500 billion lines of data on marijuana retail and cultivation — the industry's largest data set.Clients range from small growers to big multistate, multilocation retail and cultivation operations in the U.S.They also have some government clients.Last year, the company launched Leaf Data Systems, a product the helps the government track and monitor the cannabis industry.Licensed businesses use the software to comply with state and local laws.In 2015, MJ Freeway had revenues of $3.9 million, and its business has grown 340 percent over the past three years.The market for MJ Freeway's products could double if marijuana legislation passes in every state where it is on the ballot and states implement robust, well-funded programs, said Jessica Billingsley, chief operating officer.

"Every time a new state or a new market implements a successful program, that has a direct tie and benefit to our company as a technology provider to those operators," said Billingsley.The California vote on adult use marijuana is particularly important, said Chief Executive Officer Amy Poinsett.It will put a regulatory framework around a very large, unregulated market, she said.The Golden State is already the nation's largest marijuana producer and consumer and if California goes legal, the rest of the country may follow .Hypur is a financial services company that provides software to help companies in cash-intensive businesses manage money and comply with government regulations.It also helps customers find banks that will accept their cash, a huge problem for many marijuana businesses given that federal law still prohibits selling marijuana and banking is federally regulated.The company works with a couple of banks in each state that are willing to accept marijuana money, and ensures that all transactions are compliant with state laws.